Non-ST-elevation myocardial infarction: Difference between revisions

No edit summary
Line 36: Line 36:
###ACC recs O2 for sats <90% (evidence indeterminant)
###ACC recs O2 for sats <90% (evidence indeterminant)
##Nitrates
##Nitrates
###no mortality benifit
###No mortality benefit
###dilates coronary arts, decr preload, slight decr afterload.  theoretically leads to decr O2 demand of heart.
###Dilates coronary arts, decr preload, slight decr afterload
###use of viagra within 24 hr can lead to profound and prolonged vasodilation and death!
###Use of viagra within 24hr can lead to profound and prolonged vasodilation (and death)
###B-block to avoid reflex tachy.
###B-block to avoid reflex tachycardia
##B-Blockers
##B-Blockers
###Goal HR is 50-60.
###Goal HR is 50-60
###Contraindicated if HR<50 or SBP<90, acute CHF or pr >240ms
###Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms
###(Decr progression from UA to MI by 13%(jama 10/88))
###(Decreases progression from UA to MI by 13%
###decr inotropic and chronotropic response to catechols, thus decr O2 consumption.
###Decr inotropic and chronotropic response to catechols
###Decr progression from UA to MI by 13%(jama 10/88)
###use dilt or verap if can't use b-block (nifedipine clearly harmful)
###Contraindicated if HR<50 or SBP<90, acute CHF or pr>240ms.
###No IV BB in ED, PO within 24 H
###use dilt or verap if cant use b-block (nifedipine clearly harmful)
###no IV BB in ED, PO within 24 H
##ACE Inhibitor
##ACE Inhibitor
###start short-acting (captopril) within 24 hours of admission
###start short-acting (captopril) w/in 24hr of admission
###reduces RR of 30 day mort by 7% (circulation 6/98)
###Reduces RR of 30 day mort by 7%
###those w/ recent MI (esp ant) and LVdysf(x) benefit most.
###Those w/ recent MI (esp ant) and LV dysfunction benefit most
##Transfusion
##Transfusion
###transfuse to keep Hb >10 (NEJM 10/01; 33% reduction in 30 day mort)
###Transfuse to keep Hb>10
##MSO4
##Magnesium
###may use if pain after 3 doses of NTG.
###may use if pain after 3 doses of NTG
###reduces pain and theoretically can decr HR and SBP and O2 demand
###Reduces pain and theoretically can decr HR and SBP and O2 demand
###use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts)
###Use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts)
#Antiplatelet
#Antiplatelet
##(plaque rupture=exposed  endothelium=platelets=thrombus)
##ASA
##ASA
###rec dose is 160-325mg chewed.
###Rec dose is 160-325mg chewed
###reduces death from MI from 12.5-6.4% (circualtion 10/02)
###Reduces death from MI by 12.5-6.4%
###inhibits COX-1, reducing thromboxane A2
###Should be used in all ACS unless contraindicated
###should be used in all ACS unless contraindicated (far better than any new drugs we have)!! (circualtion 10/02).
##Clopidogrel (plavix 300mg po then 75qd)
##Clopidogrel (plavix, 300mg po then 75qd)
###In addition to ASA
###in addition to ASA
###Used over ticlopidine b/c faster onset & less s/e
###used over ticlopidine b/c faster onset & less s/e (ttp,aplastic anemia etc).
###Mortality benifit with NSTEMI
###mortality benifit with NSTEMI
###Main risk and contraind is bleeding
###ADP antagonist, noncompet inhibits platelet adp receptor.
###CURE trial showed decr in CV death, MI or stroke by 9.3-11.5%
###main risk and contraind is bleeding (stop 7days before cabg)
##GPIIb/IIIa(-) = Eptifibatide (Integrillin)
###CURE trial showed decr in CV death, MI or stroke from 11.5% to 9.3% w/ this drug.
###High-risk pts benefit most
##GPIIb/IIIa(-) = Integrillin (eptifibatide)
####PURSUIT trial found 30 day death or MI decr from 15.7% to 14.2%
###blocks this receptor on platelet.
###Incr ICH not seen w/ use
###oral forms incr mort!!!
###Benefit if early PCI is planned; ? to no benefit if PCI not planned
###high-risk pts benefit most.
###Reserved (if no pci) for positive trop or isch/ecg changes despite ASA, lovenox, b-block etc
###Integrillin (eptifibatide) studied in PURSUIT trial, found 30 day death or MI decr from 15.7% to 14.2%.
###incr ICH not seen w/ use.
###benefit if early pci is planned, and ? to no benefit if PCI not planned
###reserved (if no pci) for positive tpi or isch/ecg changes despite asa, lovenox, b-block etc.
#Antithombotics
#Antithombotics
##(in 2002 ACC/AHA mgt of UA/NSTEMI includes class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa +/- plavix)
##Class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa
##Heparin vs. Lovenox
##Unfractionated Heparin
###class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa
###Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s
###+/- plavix in NSTEMI
##LMWH: Enoxaparin (lovenox)
###Unfractionated Heparin
###1mg/kg sc BID
####Bolus 60-70u/kg (max 5000), followed by infusion of 12-15u/kg/hr (max 1000/hr), w/ goal ptt 45-75s
###Safer (ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH)
#####activates antithrombin which prevents thrombus propagation but does NOT cause lysis
###AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hr
#####Hirudin is approved only for pts w/ HIT.
###Adjust for CrCl<30ml and extremes of weight
###LMWH: enoxaparin (lovenox)
###No need to monitor labs
####1mg/kg sc BID
##Hirudin is approved only for pts w/ HIT
####safer (20% decr in death,MI or urgent revasc w/ LMWH vs UFH)
####AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hrs
####adjust for CrCl<30ml and extremes of weight
####No needd to monitor labs!
####ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH.
#Thrombolytics  
#Thrombolytics  
##in the case of UA/NSTEMI have been shown to increase the risk of MI, with no benefit, and all the risks of TNK!
##Only useful for STEMI
#Angiography, if
#Angiography indicated if:
##Hemodynamic instability or cardiogenic shock
##Hemodynamic instability or cardiogenic shock
##Severe left ventricular dysfunction or heart failure
##Severe left ventricular dysfunction or heart failure
Line 105: Line 93:
##New or worsening mitral regurgitation or new ventricular septal defect
##New or worsening mitral regurgitation or new ventricular septal defect
##Sustained ventricular arrhythmias  
##Sustained ventricular arrhythmias  
#Early (within 24hr) referral for angiography
#Early (within 24hr) referral for angiography if:
##TIMI risk score greater than 2
##TIMI risk score greater than 2
##New or presumably new ST segment depression
##New or presumably new ST segment depression

Revision as of 22:40, 12 May 2011

Background

  1. 33% w/ confirmed MI have no CP on presentation (esp older, female, DM, CHF)
  2. 5% of NSTEMI will develop cardiogenic shock (60% mortality)
  3. Age >65 w/ MI and anemia had 33% reduction in 30 day mort if transfused to keep HCT >30
  4. Association between quantity of troponin and risk of death

Diagnosis

  1. ACS = STEMI, NSTEMI, UA
  2. Angina is considered unstable with 1 or more:
    1. Occurs for 1st time
    2. Occurs at rest
    3. Accelerating frequency or severity
  3. ECG is normal in 8% of all confirmed MI's
  4. Intensity of Rx should be based on likelihood that sx are due to acute coronary thombosis

TIMI RISK STRATIFICATION SCORE

  1. 1 point for each
    1. Age ≥65 years
    2. Presence of at least three risk factors for CHD
    3. Prior coronary stenosis of ≥50 percent
    4. Presence of ST segment deviation on admission ECG
    5. At least two anginal episodes in prior 24 hours
    6. Elevated serum cardiac biomarkers
    7. Use of aspirin in prior seven days
  2. Likelihood of mortality, new or recurrent MI, or require revascularization at 14 days
    1. Score of 0/1 - 4.7 percent
    2. Score of 2 - 8.3 percent
    3. Score of 3 - 13.2 percent
    4. Score of 4 - 19.9 percent
    5. Score of 5 - 26.2 percent
    6. Score of 6/7 - 40.9 percent

Treatment

  1. Anti-ischemia
    1. Oxygen
      1. ACC recs O2 for sats <90% (evidence indeterminant)
    2. Nitrates
      1. No mortality benefit
      2. Dilates coronary arts, decr preload, slight decr afterload
      3. Use of viagra within 24hr can lead to profound and prolonged vasodilation (and death)
      4. B-block to avoid reflex tachycardia
    3. B-Blockers
      1. Goal HR is 50-60
      2. Contraindicated if HR<50 or SBP<90, acute CHF or PR>240ms
      3. (Decreases progression from UA to MI by 13%
      4. Decr inotropic and chronotropic response to catechols
      5. use dilt or verap if can't use b-block (nifedipine clearly harmful)
      6. No IV BB in ED, PO within 24 H
    4. ACE Inhibitor
      1. start short-acting (captopril) w/in 24hr of admission
      2. Reduces RR of 30 day mort by 7%
      3. Those w/ recent MI (esp ant) and LV dysfunction benefit most
    5. Transfusion
      1. Transfuse to keep Hb>10
    6. Magnesium
      1. may use if pain after 3 doses of NTG
      2. Reduces pain and theoretically can decr HR and SBP and O2 demand
      3. Use associated with higher mortality in MI pts (and cause of higher mortality in CHF exacerbation pts)
  2. Antiplatelet
    1. ASA
      1. Rec dose is 160-325mg chewed
      2. Reduces death from MI by 12.5-6.4%
      3. Should be used in all ACS unless contraindicated
    2. Clopidogrel (plavix 300mg po then 75qd)
      1. In addition to ASA
      2. Used over ticlopidine b/c faster onset & less s/e
      3. Mortality benifit with NSTEMI
      4. Main risk and contraind is bleeding
      5. CURE trial showed decr in CV death, MI or stroke by 9.3-11.5%
    3. GPIIb/IIIa(-) = Eptifibatide (Integrillin)
      1. High-risk pts benefit most
        1. PURSUIT trial found 30 day death or MI decr from 15.7% to 14.2%
      2. Incr ICH not seen w/ use
      3. Benefit if early PCI is planned; ? to no benefit if PCI not planned
      4. Reserved (if no pci) for positive trop or isch/ecg changes despite ASA, lovenox, b-block etc
  3. Antithombotics
    1. Class1A evidence to anticoagulate w/ heparin or lovenox along w/ asa
    2. Unfractionated Heparin
      1. Bolus 60-70u/kg (max 5000) followed by infusion of 12-15u/kg/hr (max 1000/hr), goal ptt 45-75s
    3. LMWH: Enoxaparin (lovenox)
      1. 1mg/kg sc BID
      2. Safer (ESSENCE showed 20% decr in death, MI or urgent revasc w/ LMWH vs UFH)
      3. AHA recomends for mod & high risk UA/NSTEMI unless CABG w/in 24hr
      4. Adjust for CrCl<30ml and extremes of weight
      5. No need to monitor labs
    4. Hirudin is approved only for pts w/ HIT
  4. Thrombolytics
    1. Only useful for STEMI
  5. Angiography indicated if:
    1. Hemodynamic instability or cardiogenic shock
    2. Severe left ventricular dysfunction or heart failure
    3. Recurrent or persistent rest angina despite intensive medical therapy
    4. New or worsening mitral regurgitation or new ventricular septal defect
    5. Sustained ventricular arrhythmias
  6. Early (within 24hr) referral for angiography if:
    1. TIMI risk score greater than 2
    2. New or presumably new ST segment depression
    3. Elevated cardiac enzymes
    4. Prior PCI within six months or prior CABG
    5. Recurrent angina or ischemia at rest or with low level activity despite intensive antiischemic therapy
    6. LVEF <40 percent

See Also

Cards: Cocaine CP

Source

EM Practice

UpToDate